Jean Gariépy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean Gariépy has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Prodeus
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
9 shared publications Marzena Cydzik
Physical Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada
7 shared publications- Nicholas William Fischer
Program in Genetics and Genome Biology, The Hospital for Sick Children; Toronto, Ontario, Canada
6 shared publications Aws Abdul-Wahid
Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
5 shared publicationsAmirul Islam Mallick
Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada
2 shared publicationsAws Abdul‐Wahid
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
2 shared publications
Latest Publications
- Open Access
- 1 September 2018
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 12, 350-358
A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo
- 1 September 2018
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 12, 350-358
Open AccessA Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo
- Open Access
- 9 August 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (15)
Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity
BACKGROUND. There is currently no clinical distinction between different TP53 mutations, despite increasing evidence that not all mutations have equally deleterious effects on the activity of the encoded tumor suppressor protein p53. The objective of this study was to determine whether these biological differences have clinical significance. METHODS. This retrospective cohort analysis included 2,074 patients with sporadic TP53 mutations (403 unique mutations) and 1,049 germline TP53 mutation carriers (188 unique mutations). Survival was projected by stratifying patients according to their p53 mutant–specific residual transcriptional activity scores. RESULTS. Pan-cancer survival analyses revealed a strong association between increased mutant p53 residual activity and improved survival in males with glioma and gastric adenocarcinoma ( P = 0.002 and P = 0.02) that was not present in the female cohorts ( P = 0.16 and P = 0.50). Male glioma and gastric cancer patients with TP53 mutations resulting in >5% transcriptional activity had 3.1-fold (95% CI, 2.4–3.8; P = 0.002; multivariate analysis hazard ratio [HR]) and 4.6-fold (95% CI, 3.7–5.6; P = 0.001; multivariate analysis HR) lower risk of death as compared with patients harboring inactive (0% activity) p53 mutants. The correlation between mutant p53 residual activity with survival was recapitulated in the dataset of germline TP53 mutation carriers (HR = 3.0, 95% CI, 2.7–3.4, P < 0.001 [females]; HR = 2.2, 95% CI, 1.8–2.6, P < 0.001 [males]), where brain and gastric tumors were more common among males ( P < 0.001 and P = 0.001, respectively). CONCLUSION. The retention of mutant p53 transcriptional activity prognosticates superior survival for men with glioma and gastric adenocarcinoma harboring sporadic TP53 mutations. Among germline TP53 mutation carriers, increased residual transcriptional activity is correlated with prolonged lifetime cancer survival and delayed tumor onset, and males are more prone to develop brain and gastric tumors. FUNDING. Canadian Institutes of Health Research (no. 148556).
- 9 August 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (15)
Open AccessSurvival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity
BACKGROUND. There is currently no clinical distinction between different TP53 mutations, despite increasing evidence that not all mutations have equally deleterious effects on the activity of the encoded tumor suppressor protein p53. The objective of this study was to determine whether these biological differences have clinical significance. METHODS. This retrospective cohort analysis included 2,074 patients with sporadic TP53 mutations (403 unique mutations) and 1,049 germline TP53 mutation carriers (188 unique mutations). Survival was projected by stratifying patients according to their p53 mutant–specific residual transcriptional activity scores. RESULTS. Pan-cancer survival analyses revealed a strong association between increased mutant p53 residual activity and improved survival in males with glioma and gastric adenocarcinoma ( P = 0.002 and P = 0.02) that was not present in the female cohorts ( P = 0.16 and P = 0.50). Male glioma and gastric cancer patients with TP53 mutations resulting in >5% transcriptional activity had 3.1-fold (95% CI, 2.4–3.8; P = 0.002; multivariate analysis hazard ratio [HR]) and 4.6-fold (95% CI, 3.7–5.6; P = 0.001; multivariate analysis HR) lower risk of death as compared with patients harboring inactive (0% activity) p53 mutants. The correlation between mutant p53 residual activity with survival was recapitulated in the dataset of germline TP53 mutation carriers (HR = 3.0, 95% CI, 2.7–3.4, P < 0.001 [females]; HR = 2.2, 95% CI, 1.8–2.6, P < 0.001 [males]), where brain and gastric tumors were more common among males ( P < 0.001 and P = 0.001, respectively). CONCLUSION. The retention of mutant p53 transcriptional activity prognosticates superior survival for men with glioma and gastric adenocarcinoma harboring sporadic TP53 mutations. Among germline TP53 mutation carriers, increased residual transcriptional activity is correlated with prolonged lifetime cancer survival and delayed tumor onset, and males are more prone to develop brain and gastric tumors. FUNDING. Canadian Institutes of Health Research (no. 148556).
- Open Access
- 14 May 2018
- Published by Wiley in International Journal of Cancer
- Vol. 143 (8) , 1963-1977
Serum‐derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA‐expressing tumor cells
Elevated levels of the carcinoembryonic antigen (CEA; CEACAM5) in the serum of colorectal cancer (CRC) patients represent a clinical biomarker that correlates with disease recurrence. However, a mechanistic role for soluble CEA (sCEA) in tumor progression and metastasis remains to be established. In our study, we report that sCEA acts as a paracrine factor, activating human fibroblasts by signaling through both the STAT3 and AKT1‐mTORC1 pathways, promoting their transition to a cancer‐associated fibroblast (CaF) phenotype. sCEA‐activated fibroblasts express and secrete higher levels of fibronectin, including cellular EDA+‐fibronectin (Fn‐EDA) that selectively promote the implantation and adherence of CEA‐expressing cancer cells. Immunohistochemical analyses of liver tissues derived from CRC patients with elevated levels of sCEA reveal that the expression of cellular Fn‐EDA co‐registers with CEA‐expressing liver metastases. Taken together, these findings indicate a direct role for sCEA as a human fibroblast activation factor, in priming target tissues for the engraftment of CEA‐expressing cancer cells, through the differentiation of tissue‐resident fibroblasts, resulting in a local change in composition of the extracellular matrix.
- 14 May 2018
- Published by Wiley in International Journal of Cancer
- Vol. 143 (8) , 1963-1977
Open AccessSerum‐derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA‐expressing tumor cells
Elevated levels of the carcinoembryonic antigen (CEA; CEACAM5) in the serum of colorectal cancer (CRC) patients represent a clinical biomarker that correlates with disease recurrence. However, a mechanistic role for soluble CEA (sCEA) in tumor progression and metastasis remains to be established. In our study, we report that sCEA acts as a paracrine factor, activating human fibroblasts by signaling through both the STAT3 and AKT1‐mTORC1 pathways, promoting their transition to a cancer‐associated fibroblast (CaF) phenotype. sCEA‐activated fibroblasts express and secrete higher levels of fibronectin, including cellular EDA+‐fibronectin (Fn‐EDA) that selectively promote the implantation and adherence of CEA‐expressing cancer cells. Immunohistochemical analyses of liver tissues derived from CRC patients with elevated levels of sCEA reveal that the expression of cellular Fn‐EDA co‐registers with CEA‐expressing liver metastases. Taken together, these findings indicate a direct role for sCEA as a human fibroblast activation factor, in priming target tissues for the engraftment of CEA‐expressing cancer cells, through the differentiation of tissue‐resident fibroblasts, resulting in a local change in composition of the extracellular matrix.
- Open Access
- 21 September 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (18)
VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce inflammatory responses remains untapped, largely due to the inability to derive agonists targeting its unknown receptor. A dimeric construct of the IgV domain of VISTA (VISTA-Fc) was shown to suppress the activation of T cells in vitro. However, this effect required its immobilization on a solid surface, suggesting that VISTA-Fc may display limited efficacy as a VISTA-receptor agonist in vivo. Herein, we have designed a stable pentameric VISTA construct (VISTA.COMP) by genetically fusing its IgV domain to the pentamerization domain from the cartilage oligomeric matrix protein (COMP). In contrast to VISTA-Fc, VISTA.COMP does not require immobilization to inhibit the proliferation of CD4 + T cells undergoing polyclonal activation. Furthermore, we show that VISTA.COMP, but not VISTA-Fc, functions as an immunosuppressive agonist in vivo capable of prolonging the survival of skin allografts in a mouse transplant model as well as rescuing mice from acute concanavalin-A–induced hepatitis. Collectively, we believe our data demonstrate that VISTA.COMP is a checkpoint receptor agonist and the first agent to our knowledge targeting the putative VISTA-receptor to suppress T cell–mediated immune responses.
- 21 September 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (18)
Open AccessVISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce inflammatory responses remains untapped, largely due to the inability to derive agonists targeting its unknown receptor. A dimeric construct of the IgV domain of VISTA (VISTA-Fc) was shown to suppress the activation of T cells in vitro. However, this effect required its immobilization on a solid surface, suggesting that VISTA-Fc may display limited efficacy as a VISTA-receptor agonist in vivo. Herein, we have designed a stable pentameric VISTA construct (VISTA.COMP) by genetically fusing its IgV domain to the pentamerization domain from the cartilage oligomeric matrix protein (COMP). In contrast to VISTA-Fc, VISTA.COMP does not require immobilization to inhibit the proliferation of CD4 + T cells undergoing polyclonal activation. Furthermore, we show that VISTA.COMP, but not VISTA-Fc, functions as an immunosuppressive agonist in vivo capable of prolonging the survival of skin allografts in a mouse transplant model as well as rescuing mice from acute concanavalin-A–induced hepatitis. Collectively, we believe our data demonstrate that VISTA.COMP is a checkpoint receptor agonist and the first agent to our knowledge targeting the putative VISTA-receptor to suppress T cell–mediated immune responses.
- 4 November 2016
- Published by Taylor & Francis in Cell Cycle
- Vol. 15 (23) , 3210-3219
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis
Mutations in the oligomerization domain of p53 are genetically linked to cancer susceptibility in Li-Fraumeni Syndrome. These mutations typically alter the oligomeric state of p53 and impair its transcriptional activity. Activation of p53 through tetramerization is required for its tumor suppressive function by inducing transcriptional programs that lead to cell fate decisions such as cell cycle arrest or apoptosis. How p53 chooses between these cell fate outcomes remains unclear. Here, we use 5 oligomeric variants of p53, including 2 novel p53 constructs, that yield either monomeric, dimeric or tetrameric forms of p53 and demonstrate that they induce distinct cellular activities and gene expression profiles that lead to different cell fate outcomes. We report that dimeric p53 variants are cytostatic and can arrest cell growth, but lack the ability to trigger apoptosis in p53-null cells. In contrast, p53 tetramers induce rapid apoptosis and cell growth arrest, while a monomeric variant is functionally inactive, supporting cell growth. In particular, the expression of pro-arrest CDKN1A and pro-apoptotic P53AIP1 genes are important cell fate determinants that are differentially regulated by the oligomeric state of p53. This study suggests that the most abundant oligomeric species of p53 present in resting cells, namely p53 dimers, neither promote cell growth or cell death and that shifting the oligomeric state equilibrium of p53 in cells toward monomers or tetramers is a key parameter in p53-based cell fate decisions.
- 4 November 2016
- Published by Taylor & Francis in Cell Cycle
- Vol. 15 (23) , 3210-3219
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis
Mutations in the oligomerization domain of p53 are genetically linked to cancer susceptibility in Li-Fraumeni Syndrome. These mutations typically alter the oligomeric state of p53 and impair its transcriptional activity. Activation of p53 through tetramerization is required for its tumor suppressive function by inducing transcriptional programs that lead to cell fate decisions such as cell cycle arrest or apoptosis. How p53 chooses between these cell fate outcomes remains unclear. Here, we use 5 oligomeric variants of p53, including 2 novel p53 constructs, that yield either monomeric, dimeric or tetrameric forms of p53 and demonstrate that they induce distinct cellular activities and gene expression profiles that lead to different cell fate outcomes. We report that dimeric p53 variants are cytostatic and can arrest cell growth, but lack the ability to trigger apoptosis in p53-null cells. In contrast, p53 tetramers induce rapid apoptosis and cell growth arrest, while a monomeric variant is functionally inactive, supporting cell growth. In particular, the expression of pro-arrest CDKN1A and pro-apoptotic P53AIP1 genes are important cell fate determinants that are differentially regulated by the oligomeric state of p53. This study suggests that the most abundant oligomeric species of p53 present in resting cells, namely p53 dimers, neither promote cell growth or cell death and that shifting the oligomeric state equilibrium of p53 in cells toward monomers or tetramers is a key parameter in p53-based cell fate decisions.
- 31 March 2016
- Published by Wiley in International Journal of Cancer
- Vol. 139 (4) , 841-853
Induction of antigen‐specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment
The engraftment of circulating cancer cells at distal sites represents a key step in the metastatic cascade, yet remains an unexplored target for therapeutic intervention. In this study, we establish that a vaccination strategy yielding an antigen‐specific TH9 response induces long term host surveillance and prevents the engraftment of circulating cancer cells. Specifically, we show that vaccination with a recombinant CEA IgV‐like N domain, formulated with the TLR3 ligand poly I:C, elicits a CEA‐specific TH9 response, wherein IL‐9 secreting TH cells act in concert with CEA N domain‐specific antibodies as well as activated mast cells in preventing tumor cell engraftment. The development of this immune response was dependent on TLR3, since interference with the TLR3‐dsRNA complex formation led to a reduction in vaccine‐imparted protection and a shift in the resulting immune response toward a TH2 response. These findings point to the existence of an alternate tumor targeting immune mechanism that can be exploited for the purpose of developing vaccine therapies targeting tumor dissemination and engraftment.
- 31 March 2016
- Published by Wiley in International Journal of Cancer
- Vol. 139 (4) , 841-853
Induction of antigen‐specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment
The engraftment of circulating cancer cells at distal sites represents a key step in the metastatic cascade, yet remains an unexplored target for therapeutic intervention. In this study, we establish that a vaccination strategy yielding an antigen‐specific TH9 response induces long term host surveillance and prevents the engraftment of circulating cancer cells. Specifically, we show that vaccination with a recombinant CEA IgV‐like N domain, formulated with the TLR3 ligand poly I:C, elicits a CEA‐specific TH9 response, wherein IL‐9 secreting TH cells act in concert with CEA N domain‐specific antibodies as well as activated mast cells in preventing tumor cell engraftment. The development of this immune response was dependent on TLR3, since interference with the TLR3‐dsRNA complex formation led to a reduction in vaccine‐imparted protection and a shift in the resulting immune response toward a TH2 response. These findings point to the existence of an alternate tumor targeting immune mechanism that can be exploited for the purpose of developing vaccine therapies targeting tumor dissemination and engraftment.
- Open Access
- 1 August 2015
- Published by Wiley in The FASEB Journal
- Vol. 29 (8) , 3493-3505
Slow binding kinetics of secreted protein, acidic, rich in cysteine-VEGF interaction limit VEGF activation of VEGF receptor 2 and attenuate angiogenesis
VEGF-A (VEGF) drives angiogenesis through activation of downstream effectors to promote endothelial cell proliferation and migration. Although VEGF binds both VEGF receptor 1 (R1) and receptor 2 (R2)...
- 1 August 2015
- Published by Wiley in The FASEB Journal
- Vol. 29 (8) , 3493-3505
Open AccessSlow binding kinetics of secreted protein, acidic, rich in cysteine-VEGF interaction limit VEGF activation of VEGF receptor 2 and attenuate angiogenesis
VEGF-A (VEGF) drives angiogenesis through activation of downstream effectors to promote endothelial cell proliferation and migration. Although VEGF binds both VEGF receptor 1 (R1) and receptor 2 (R2)...
- Open Access
- 1 January 2015
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 4 (4) , e237
Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
- 1 January 2015
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 4 (4) , e237
Open AccessTargeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
- Open Access
- 1 January 2014
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 3 (8) , e190
Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival
- 1 January 2014
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 3 (8) , e190
Open AccessAgonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival
- Open Access
- 17 December 2013
- Published by Wiley in Molecular Oncology
- Vol. 8 (2) , 337-350
The carcinoembryonic antigen IgV‐like N domain plays a critical role in the implantation of metastatic tumor cells
The human carcinoembryonic antigen (CEA) is a cell adhesion molecule involved in both homotypic and heterotypic interactions. The aberrant overexpression of CEA on adenocarcinoma cells correlates with their increased metastatic potential. Yet, the mechanism(s) by which its adhesive properties can lead to the implantation of circulating tumor cells and expansion of metastatic foci remains to be established. In this study, we demonstrate that the IgV‐like N terminal domain of CEA directly participates in the implantation of cancer cells through its homotypic and heterotypic binding properties. Specifically, we determined that the recombinant N terminal domain of CEA directly binds to fibronectin (Fn) with a dissociation constant in the nanomolar range (KD 16 ± 3 nM) and interacts with itself (KD 100 ± 17 nM) and more tightly to the IgC‐like A3 domain (KD 18 ± 3 nM). Disruption of these molecular associations through the addition of antibodies specific to the CEA N or A3B3 domains, or by adding soluble recombinant forms of the CEA N, A3 or A3B3 domains or a peptide corresponding to residues 108–115 of CEA resulted in the inhibition of CEA‐mediated intercellular aggregation and adherence events in vitro. Finally, pretreating CEA‐expressing murine colonic carcinoma cells (MC38.CEA) with rCEA N, A3 or A3B3 modules blocked their implantation and the establishment of tumor foci in vivo. Together, these results suggest a new mechanistic insight into how the CEA IgV‐like N domain participates in cellular events that can have a macroscopic impact in terms of cancer progression and metastasis.
- 17 December 2013
- Published by Wiley in Molecular Oncology
- Vol. 8 (2) , 337-350
Open AccessThe carcinoembryonic antigen IgV‐like N domain plays a critical role in the implantation of metastatic tumor cells
The human carcinoembryonic antigen (CEA) is a cell adhesion molecule involved in both homotypic and heterotypic interactions. The aberrant overexpression of CEA on adenocarcinoma cells correlates with their increased metastatic potential. Yet, the mechanism(s) by which its adhesive properties can lead to the implantation of circulating tumor cells and expansion of metastatic foci remains to be established. In this study, we demonstrate that the IgV‐like N terminal domain of CEA directly participates in the implantation of cancer cells through its homotypic and heterotypic binding properties. Specifically, we determined that the recombinant N terminal domain of CEA directly binds to fibronectin (Fn) with a dissociation constant in the nanomolar range (KD 16 ± 3 nM) and interacts with itself (KD 100 ± 17 nM) and more tightly to the IgC‐like A3 domain (KD 18 ± 3 nM). Disruption of these molecular associations through the addition of antibodies specific to the CEA N or A3B3 domains, or by adding soluble recombinant forms of the CEA N, A3 or A3B3 domains or a peptide corresponding to residues 108–115 of CEA resulted in the inhibition of CEA‐mediated intercellular aggregation and adherence events in vitro. Finally, pretreating CEA‐expressing murine colonic carcinoma cells (MC38.CEA) with rCEA N, A3 or A3B3 modules blocked their implantation and the establishment of tumor foci in vivo. Together, these results suggest a new mechanistic insight into how the CEA IgV‐like N domain participates in cellular events that can have a macroscopic impact in terms of cancer progression and metastasis.